AOCI at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's AOCI?
- Corvus Pharmaceuticals (CRVS) reported AOCI of -$1.13M in Q1 2026.
- How has Corvus Pharmaceuticals's AOCI changed year-over-year?
- Corvus Pharmaceuticals's AOCI increased by 10.2% year-over-year, from -$1.25M to -$1.13M.
- What is the long-term trend for Corvus Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's AOCI has grown at a 195.2% compound annual growth rate (CAGR), from $4K to -$896K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.